| Assessment Status | Rapid review complete |
| HTA ID | 21063 |
| Drug | Dupilumab |
| Brand | Dupixent® |
| Indication | For adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance. |
| Assessment Process | |
| Rapid review commissioned | 13/12/2021 |
| Rapid review completed | 08/02/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that dupilumab (Dupixent®) not be considered for reimbursement at the submitted price* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations November 2023.
